WO2026038147 - CENTANAFADINE MULTIPHASIC CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION
National phase entry is expected:
Publication Number
WO/2026/038147
Publication Date
19.02.2026
International Application No.
PCT/IB2025/058206
International Filing Date
12.08.2025
Title **
[English]
CENTANAFADINE MULTIPHASIC CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION
[French]
FORMULATION PHARMACEUTIQUE À LIBÉRATION CONTRÔLÉE MULTIPHASIQUE DE CENTANAFADINE
Applicants **
PATEL, Jayendrakumar Dasharathlal
Inventors
PATEL, Jayendrakumar Dasharathlal
Priority Data
18/801,899
13.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2037 | |
| EPO | Filing, Examination, Granting | 8725 | |
| Japan | Filing, Examination, Granting | 2061 | |
| South Korea | Filing, Examination, Granting | 1937 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,500
Contact Us
Abstract[English]
A centanafadine multiphasic controlled-release pharmaceutical formulation comprising a centanafadine continuous phase surrounding a centanafadine particulate phase, wherein the amount of centanafadine contained in the centanafadine continuous phase facilitates a first release rate of the centanafadine, and the amount of centanafadine contained in the centanafadine particulate phase facilitates the second and/or third release rate of the centanafadine. The centanafadine particulate phase is formulated in the form of a plurality of the centanafadine particulates and the centanafadine continues phase is formulated in the form of centanafadine burst release coat surrounding one or more centanafadine particulates of the plurality of the centanafadine particulates. The related method of making the pharmaceutical formulation, and treatment of the disease conditions using the centanafadine multiphasic controlled-release pharmaceutical formulation is also disclosed herein.[French]
L'invention concerne une formulation pharmaceutique à libération contrôlée multiphasique de centanafadine comprenant une phase continue de centanafadine entourant une phase particulaire de centanafadine, la quantité de centanafadine contenue dans la phase continue de centanafadine permettant d'obtenir une première vitesse de libération de la centanafadine, et la quantité de centanafadine contenue dans la phase particulaire de centanafadine permettant d'obtenir la deuxième et/ou la troisième vitesse de libération de la centanafadine. La phase particulaire de centanafadine est formulée sous la forme d'une pluralité de particules de centanafadine et la phase continue de centanafadine est formulée sous la forme d'une couche de libération rapide de centanafadine entourant une ou plusieurs particules de centanafadine de la pluralité de particules de centanafadine. L'invention concerne également le procédé associé de fabrication de la formulation pharmaceutique, et le traitement d'états pathologiques à l'aide de la formulation pharmaceutique à libération contrôlée multiphasique de centanafadine.